无导线起搏器作为缓慢性心律失常治疗领域的新星,已经在临床试验中得到了广泛关注与研究。其中,Micra是目前国内唯一使用的无导线心脏起搏器,其应用消除了与传统经静脉起搏导线和皮下囊袋相关并发症,减少了锁骨下静脉穿刺可能引发的血...无导线起搏器作为缓慢性心律失常治疗领域的新星,已经在临床试验中得到了广泛关注与研究。其中,Micra是目前国内唯一使用的无导线心脏起搏器,其应用消除了与传统经静脉起搏导线和皮下囊袋相关并发症,减少了锁骨下静脉穿刺可能引发的血胸、气胸等相关并发症,但其使用存在较高的心包积液/穿孔风险。对于高危及特殊人群,无导线起搏器同样展现出了其可行性和安全性。此外,与传统的经静脉起搏器相比,亦显著提升患者的生活质量。本文结合近年来的相关研究报道,现就无导线心脏起搏器的技术进展、安全性和有效性研究、优势、与多种起搏方式的联合应用、挑战与展望等方面做一综述。As a rising star in the field of bradycardia treatment, leadless pacemakers have attracted significant attention and been tested in clinical trials. Among the leadless pacemakers, Micra is currently the only one used domestically. Its application eliminated complications associated with traditional transvenous pacing leads and subcutaneous pockets, and reduced the risk of hemothorax, pneumothorax, and other related complications that may be caused by subclavian vein puncture. However, there is a higher risk of pericardial effusion/perforation in the application of Micra. For high-risk and special patient populations, leadless pacemakers have also showed demonstrable feasibility and safety. Moreover, compared with traditional transvenous pacemaker, leadless pacemakers significantly improve patients’ quality of life. This article combines relevant research reports in recent years to provide a comprehensive review of the technological advancements, safety and effectiveness studies, advantages, combined applications with various pacing methods, challenges, and the future of leadless cardiac pacemakers.展开更多
文摘无导线起搏器作为缓慢性心律失常治疗领域的新星,已经在临床试验中得到了广泛关注与研究。其中,Micra是目前国内唯一使用的无导线心脏起搏器,其应用消除了与传统经静脉起搏导线和皮下囊袋相关并发症,减少了锁骨下静脉穿刺可能引发的血胸、气胸等相关并发症,但其使用存在较高的心包积液/穿孔风险。对于高危及特殊人群,无导线起搏器同样展现出了其可行性和安全性。此外,与传统的经静脉起搏器相比,亦显著提升患者的生活质量。本文结合近年来的相关研究报道,现就无导线心脏起搏器的技术进展、安全性和有效性研究、优势、与多种起搏方式的联合应用、挑战与展望等方面做一综述。As a rising star in the field of bradycardia treatment, leadless pacemakers have attracted significant attention and been tested in clinical trials. Among the leadless pacemakers, Micra is currently the only one used domestically. Its application eliminated complications associated with traditional transvenous pacing leads and subcutaneous pockets, and reduced the risk of hemothorax, pneumothorax, and other related complications that may be caused by subclavian vein puncture. However, there is a higher risk of pericardial effusion/perforation in the application of Micra. For high-risk and special patient populations, leadless pacemakers have also showed demonstrable feasibility and safety. Moreover, compared with traditional transvenous pacemaker, leadless pacemakers significantly improve patients’ quality of life. This article combines relevant research reports in recent years to provide a comprehensive review of the technological advancements, safety and effectiveness studies, advantages, combined applications with various pacing methods, challenges, and the future of leadless cardiac pacemakers.
